文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

根治剂量盆腔放疗对新诊断器官转移性宫颈癌原发灶的疗效

Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.
PubMed 文献 · Radiat Oncol · 2019-05-20

该回顾性研究纳入48例新诊断器官转移性宫颈癌患者,比较化疗联合根治性盆腔放疗(A组36例)与化疗联合或不联合姑息性盆腔放疗(B组12例)的生存差异。结果显示A组中位总生存17.3个月优于B组10个月,多因素分析A组死亡风险显著降低(HR 0.32,95%CI 0.15-0.67,p=0.003)。

要点

  • 化疗联合根治性盆腔放疗较化疗联合或不联合姑息性盆腔放疗改善总生存。
  • 多因素分析显示联合根治性盆腔放疗与较低死亡风险相关(HR 0.32)。
  • 全队列75%患者治疗失败主要原因为远处转移病灶进展。

核心结论

  • 在体能状态良好的器官转移性宫颈癌患者中,化疗联合根治性盆腔放疗与化疗联合或不联合姑息性盆腔放疗相比,与改善的生存结局相关。

研究设计与样本

  • 回顾性分析2006年10月至2016年12月浙江省肿瘤医院收治的新诊断器官转移性宫颈癌且均接受化疗的患者病历。
  • 从11982例原发宫颈癌患者中识别出48例,按治疗方式分为A组36例(化疗联合根治性盆腔放疗)和B组12例(化疗联合或不联合姑息性盆腔放疗)。
  • 采用Kaplan-Meier法比较生存时间,单因素log-rank法和多因素Cox比例风险模型识别与生存相关的变量。

主要发现

  • 中位随访14.4个月(范围4.6-114.7个月)。
  • A组和B组的中位总生存分别为17.3个月和10个月。
  • 单因素分析显示A组总生存优于B组(p=0.002)。
  • 多因素分析显示A组与B组相比死亡风险更低(HR 0.32;95%CI 0.15-0.67,p=0.003)。
  • 全队列中36例(75%)治疗失败的主要原因为远处转移病灶进展。

临床怎么用

  • 对于体能状态良好的新诊断器官转移性宫颈癌患者,可考虑化疗联合根治性盆腔放疗以改善生存。
  • 治疗失败主要源于远处转移进展,提示需关注全身治疗及远处病灶控制。

局限性

  • 本研究为单中心回顾性研究,样本量较小(共48例,B组仅12例)。
  • 原文未报告前瞻性随机对照证据,结论需前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical efficacy of definitive pelvic radiotherapy for primary tumors in patients with newly diagnosed organ metastatic cervical cancer is unclear. Therefore, we conducted a retrospective study to evaluate the efficacy of definitive pelvic radiotherapy combined with systemic chemotherapy in patients with organ metastatic cervical cancer. METHODS: We retrospectively analysed medical records from patients with newly diagnosed organ metastatic cervical cancer, all treated with chemotherapy at the Zhejiang Cancer Hospital between October 2006 and December 2016. Survival times were compared using the Kaplan-Meier method. The univariate log-rank method and multivariate Cox proportional hazard models were used to identify associated variables with survival. RESULTS: A total of 48 patients were identified from 11,982 primary cervical cancer patients and divided into two groups according to treatment mode: 36 patients received chemotherapy combined with definitive pelvic radiotherapy (group A), 12 patients underwent chemotherapy with/without palliative pelvic radiotherapy (group B). Median follow-up was 14.4 months (range, 4.6-114.7 months). Median overall survival (OS) for group A and group B was 17.3 and 10 months, respectively. Using the univariate analysis, group A was found to have a better OS than group B (p = 0.002). In multivariate analysis, group A (hazard ratio [HR], 0.32; 95% confidence interval [CI], 0.15-0.67, p = 0.003) was associated with lower risk of death compared with group B. The main reason for treatment failure was found to be due to the progression of distant metastatic lesions in 36 patients (75%) from the whole cohort. CONCLUSION: In this cohort of organ metastatic cervical cancer patients in good performance status, chemotherapy combined with definitive pelvic radiotherapy was associated with improved survival outcomes when compared with chemotherapy with/without palliative pelvic radiotherapy. Prospective trials evaluating definitive pelvic radiotherapy for newly diagnosed organ metastatic cervical cancer, therefore, are warranted.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yin Z, Lou H, Tang H, et al. Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer. Radiat Oncol. 2019. PMID: 31109371. doi:10.1186/s13014-019-1297-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。